MuDelta: Phase II started

Furiex began a placebo-controlled, double-blind, dose-escalation, U.S. Phase II trial in 850 patients to evaluate 5, 25, 100 and 200 mg oral MuDelta given twice daily. Furiex, which spun out of PPD I...